Takeda Pharmaceutical has entered a partnership agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop a drug for visceral leishmaniasis (VL).

The organisations will perform preclinical and Phase I trials on drug candidates that are among the aminopyrazole class of compounds.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Global Health Innovative Technology Fund (GHIT), a public private partnership fund, will sponsor the project and will donate around JPY600m ($5.59m).

The primary objective of the programme is to deliver an orally active, safe, effective, short-course, field-adapted drug that can be given along with another oral formulation to potentially avoid resistance.

The organisations plan to build alliances and develop new approaches to improve access to medicines for the development of neglected tropical disease treatments.

“The primary objective of the programme is to deliver an orally active, safe, effective, short-course, field-adapted drug.”

The Neglected Tropical Diseases Drug Discovery Booster project was also launched by the organisations in 2015 to boost drug discovery targeting leishmaniasis and Chagas disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Transmitted through sandfly bites, VL is the most serious type of leishmaniasis, and affects more than one billion people in more than 90 countries.

the disease is characterised by fever, weight loss, spleen and liver enlargement and anaemia, and leads to nearly 30,000 deaths per year.

Takeda and DNDi previously partnered in July 2015 in the Lead Optimization Programme aimed at establishing the best aminopyrazole compound to develop a new drug for VL.

Takeda has also signed an agreement to sell its Brazil-based subsidiary Multilab to the local medical equipment company Novamed. Multilab is involved in the research, development, manufacture and sale of pharmaceutical products.